Premium
Innovative Clinical Trials: The LUNG‐MAP Study
Author(s) -
Steuer CE,
Papadimitrakopoulou V,
Herbst RS,
Redman MW,
Hirsch FR,
Mack PC,
Ramalingam SS,
Gandara DR
Publication year - 2015
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.88
Subject(s) - lung cancer , clinical trial , medicine , oncology , adenocarcinoma , drug development , biomarker , targeted therapy , basal cell , cancer , drug , pharmacology , biology , biochemistry
Although the proportion of patients with squamous cell carcinoma of the lung has declined over the last two decades, the disease is still fatal for tens of thousands of patients each year. The treatment of non–small cell lung cancer has advanced rapidly over the past decade, providing novel, targeted therapeutic options to patients, but has mostly been limited to the adenocarcinoma histology. Efforts are currently underway to bring squamous cell carcinoma of the lung into this new era of targeted therapy. This article reviews the rationale and trial design for the “LUNG‐MAP: S1400 Phase II/III Biomarker‐Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer” study. This multi‐institutional, multi‐cooperative group trial aims to individualize treatment for patients with metastatic squamous cell carcinoma to one of five arms based on the genomic profile of the tumor. The goal of this clinical trial is to rapidly identify new active drugs and bring them as soon as possible through a registration process for patients with squamous cell lung cancer by utilizing a novel trial design and involving all key stakeholders in drug development in a national effort. This could serve as a paradigm for drug development for malignancies with wide molecular heterogeneity.